Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06835375 in Primary Immune Thrombocytopenia
NCT05070845Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Feb 2022
- Primary completion
- Sep 2026
- Modality
- Antibody Conjugates, scFv Fragments, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of PF-06835375 in primary immune thrombocytopenia (ITP), sponsored by Pfizer. Started Feb 2022; status: terminated.
02
Drugs
PF-06835375
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05070845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05070845.